CCL2 and atherosclerosis: Ezetimibe debilitates atherosclerosis caused by lipid-lowering and reduces circulating inflammatory cytokines in the lesion focuses such as monocyte chemoattractant protein (MCP-1) and tumor necrosis factor (TNF-α) [55].